The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death
Authors
Keywords
-
Journal
NATURE MEDICINE
Volume 22, Issue 6, Pages 624-631
Publisher
Springer Nature
Online
2016-05-02
DOI
10.1038/nm.4078
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
- (2015) Filippo Pietrantonio et al. EUROPEAN JOURNAL OF CANCER
- Metastatic Colorectal Cancer: Current State and Future Directions
- (2015) Marwan G. Fakih JOURNAL OF CLINICAL ONCOLOGY
- Stress Responses from the Endoplasmic Reticulum in Cancer
- (2015) Hironori Kato et al. Frontiers in Oncology
- ExtendedRASmutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials
- (2014) M. J. Sorich et al. ANNALS OF ONCOLOGY
- ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
- (2014) Carlos L. Arteaga et al. CANCER CELL
- ERP57 Membrane Translocation Dictates the Immunogenicity of Tumor Cell Death by Controlling the Membrane Translocation of Calreticulin
- (2014) M. Obeid JOURNAL OF IMMUNOLOGY
- Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
- (2014) Timothy J Price et al. LANCET ONCOLOGY
- RAF Suppression Synergizes with MEK Inhibition in KRAS Mutant Cancer Cells
- (2014) Simona Lamba et al. Cell Reports
- Consensus guidelines for the detection of immunogenic cell death
- (2014) Oliver Kepp et al. OncoImmunology
- Trial Watch
- (2014) Erika Vacchelli et al. OncoImmunology
- PIK3CA, BRAF , and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17
- (2013) Christos S. Karapetis et al. CLINICAL CANCER RESEARCH
- Threshold-controlled ubiquitination of the EGFR directs receptor fate
- (2013) Sara Sigismund et al. EMBO JOURNAL
- Rare Though Not Mutually Exclusive: A Report of Three Cases of Concomitant KRAS and BRAF Mutation and a Review of the Literature
- (2013) Ibrahim Halil Sahin et al. Journal of Cancer
- Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
- (2012) Carsten Bokemeyer et al. EUROPEAN JOURNAL OF CANCER
- Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: Analysis of data from the EXTREME and CRYSTAL studies
- (2012) Lisa Licitra et al. EUROPEAN JOURNAL OF CANCER
- The secret ally: immunostimulation by anticancer drugs
- (2012) Lorenzo Galluzzi et al. NATURE REVIEWS DRUG DISCOVERY
- Impact of the Specific Mutation inKRASCodon 12 Mutated Tumors on Treatment Efficacy in Patients with Metastatic Colorectal Cancer Receiving Cetuximab-Based First-Line Therapy: A Pooled Analysis of Three Trials
- (2012) Dominik P. Modest et al. ONCOLOGY
- Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
- (2011) C. Bokemeyer et al. ANNALS OF ONCOLOGY
- Biologic therapies in the metastatic colorectal cancer treatment continuum – Applying current evidence to clinical practice
- (2011) Marc Peeters et al. CANCER TREATMENT REVIEWS
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Induction of Immunogenic Apoptosis by Blockade of Epidermal Growth Factor Receptor Activation with a Specific Antibody
- (2011) Greta Garrido et al. JOURNAL OF IMMUNOLOGY
- Andromeda: A Peptide Search Engine Integrated into the MaxQuant Environment
- (2011) Jürgen Cox et al. JOURNAL OF PROTEOME RESEARCH
- Immunogenic Tumor Cell Death for Optimal Anticancer Therapy: The Calreticulin Exposure Pathway
- (2010) L. Zitvogel et al. CLINICAL CANCER RESEARCH
- GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists
- (2009) Eran Eden et al. BMC BIOINFORMATICS
- PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer
- (2009) H. Prenen et al. CLINICAL CANCER RESEARCH
- Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death
- (2009) Theocharis Panaretakis et al. EMBO JOURNAL
- A Dual Pressure Linear Ion Trap Orbitrap Instrument with Very High Sequencing Speed
- (2009) Jesper V. Olsen et al. MOLECULAR & CELLULAR PROTEOMICS
- BRAFMutation in Metastatic Colorectal Cancer
- (2009) Jolien Tol et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunogenic death of colon cancer cells treated with oxaliplatin
- (2009) A Tesniere et al. ONCOGENE
- Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
- (2008) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation